Cargando…

Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center

BACKGROUND AND PURPOSE: To analyze clinical trial activities and patient recruitment numbers into prospective clinical studies for solid malignancies during the COVID-19 pandemic in a tertiary cancer center. MATERIALS AND METHODS: Patient recruitment numbers in prospective clinical studies of solid...

Descripción completa

Detalles Bibliográficos
Autores principales: von der Grün, Jens, Ahmadsei, Maiwand, Breyer, Isabel, Britschgi, Christian, Eberli, Daniel, Hermanns, Thomas, Mangana, Joanna, Petrowsky, Henrik, Ramelyte, Egle, Roth, Patrick, Schär, Gabriel, Opitz, Isabelle, Weller, Michael, Wicki, Andreas, Witzel, Isabell, Balermpas, Panagiotis, Guckenberger, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630114/
http://dx.doi.org/10.1016/j.neo.2023.100946
_version_ 1785132086698442752
author von der Grün, Jens
Ahmadsei, Maiwand
Breyer, Isabel
Britschgi, Christian
Eberli, Daniel
Hermanns, Thomas
Mangana, Joanna
Petrowsky, Henrik
Ramelyte, Egle
Roth, Patrick
Schär, Gabriel
Opitz, Isabelle
Weller, Michael
Wicki, Andreas
Witzel, Isabell
Balermpas, Panagiotis
Guckenberger, Matthias
author_facet von der Grün, Jens
Ahmadsei, Maiwand
Breyer, Isabel
Britschgi, Christian
Eberli, Daniel
Hermanns, Thomas
Mangana, Joanna
Petrowsky, Henrik
Ramelyte, Egle
Roth, Patrick
Schär, Gabriel
Opitz, Isabelle
Weller, Michael
Wicki, Andreas
Witzel, Isabell
Balermpas, Panagiotis
Guckenberger, Matthias
author_sort von der Grün, Jens
collection PubMed
description BACKGROUND AND PURPOSE: To analyze clinical trial activities and patient recruitment numbers into prospective clinical studies for solid malignancies during the COVID-19 pandemic in a tertiary cancer center. MATERIALS AND METHODS: Patient recruitment numbers in prospective clinical studies of solid malignancies were retrospectively analyzed for the years 2019 – 2021 at the Comprehensive Cancer Center Zurich (CCCZ). Changes in recruitment numbers were tested for association with organ-specific subunits, as well as organizational and treatment-related trial characteristics. To assess differences between categorical variables, Chi-squared test was used. For uni- and multivariate analysis, Cox proportional hazards were calculated. RESULTS: In 2019, there were a total of 107 studies (registry trials, clinical phase I-III trials, and translational studies) recruiting 304 patients at the CCCZ. During the COVID-19 pandemic in 2020 and 2021, there were 120 and 125 active trials with a total recruitment of 355 and 666 patients, respectively. No significant differences between the subunits and study characteristics in changes of patient recruitment in clinical phase I-III trials were identified when the year prior to the COVID-19 pandemic (2019) was compared to the first year of the pandemic (2020) and to 2020-2021. CONCLUSIONS: Despite healthcare systems around the world have experienced significant disruption due to the COVID-19 pandemic, data from our tertiary cancer center showed that clinical trial activities were maintained at a high level during the pandemic.
format Online
Article
Text
id pubmed-10630114
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-106301142023-11-10 Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center von der Grün, Jens Ahmadsei, Maiwand Breyer, Isabel Britschgi, Christian Eberli, Daniel Hermanns, Thomas Mangana, Joanna Petrowsky, Henrik Ramelyte, Egle Roth, Patrick Schär, Gabriel Opitz, Isabelle Weller, Michael Wicki, Andreas Witzel, Isabell Balermpas, Panagiotis Guckenberger, Matthias Neoplasia Original article BACKGROUND AND PURPOSE: To analyze clinical trial activities and patient recruitment numbers into prospective clinical studies for solid malignancies during the COVID-19 pandemic in a tertiary cancer center. MATERIALS AND METHODS: Patient recruitment numbers in prospective clinical studies of solid malignancies were retrospectively analyzed for the years 2019 – 2021 at the Comprehensive Cancer Center Zurich (CCCZ). Changes in recruitment numbers were tested for association with organ-specific subunits, as well as organizational and treatment-related trial characteristics. To assess differences between categorical variables, Chi-squared test was used. For uni- and multivariate analysis, Cox proportional hazards were calculated. RESULTS: In 2019, there were a total of 107 studies (registry trials, clinical phase I-III trials, and translational studies) recruiting 304 patients at the CCCZ. During the COVID-19 pandemic in 2020 and 2021, there were 120 and 125 active trials with a total recruitment of 355 and 666 patients, respectively. No significant differences between the subunits and study characteristics in changes of patient recruitment in clinical phase I-III trials were identified when the year prior to the COVID-19 pandemic (2019) was compared to the first year of the pandemic (2020) and to 2020-2021. CONCLUSIONS: Despite healthcare systems around the world have experienced significant disruption due to the COVID-19 pandemic, data from our tertiary cancer center showed that clinical trial activities were maintained at a high level during the pandemic. Neoplasia Press 2023-10-27 /pmc/articles/PMC10630114/ http://dx.doi.org/10.1016/j.neo.2023.100946 Text en © 2023 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original article
von der Grün, Jens
Ahmadsei, Maiwand
Breyer, Isabel
Britschgi, Christian
Eberli, Daniel
Hermanns, Thomas
Mangana, Joanna
Petrowsky, Henrik
Ramelyte, Egle
Roth, Patrick
Schär, Gabriel
Opitz, Isabelle
Weller, Michael
Wicki, Andreas
Witzel, Isabell
Balermpas, Panagiotis
Guckenberger, Matthias
Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
title Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
title_full Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
title_fullStr Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
title_full_unstemmed Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
title_short Patient recruitment into clinical studies of solid malignancies during the COVID-19 pandemic in a tertiary cancer center
title_sort patient recruitment into clinical studies of solid malignancies during the covid-19 pandemic in a tertiary cancer center
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630114/
http://dx.doi.org/10.1016/j.neo.2023.100946
work_keys_str_mv AT vondergrunjens patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT ahmadseimaiwand patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT breyerisabel patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT britschgichristian patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT eberlidaniel patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT hermannsthomas patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT manganajoanna patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT petrowskyhenrik patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT ramelyteegle patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT rothpatrick patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT schargabriel patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT opitzisabelle patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT wellermichael patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT wickiandreas patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT witzelisabell patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT balermpaspanagiotis patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter
AT guckenbergermatthias patientrecruitmentintoclinicalstudiesofsolidmalignanciesduringthecovid19pandemicinatertiarycancercenter